Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells
Song Xue1, Ying-Xia Chen1, Shu-Kui Qin1
1Department of Medical Oncology, 81 Hospital of PLA, 81 Clinical College, Anhui Medical University, Nanjing, Jiangsu 210002, P.R. China.
Abstract:
Raltitrexed is a specific inhibitor of thymidylate synthase (TS), which has been considered as a potential chemotherapeutic agent for the treatment of advanced gastric cancer. In the present study, the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells were investigated. The cytotoxic activity of raltitrexed on SGC7901 cells was determined by cell counting kit-8 (CCK-8) assay. The CCK‑8 assay indicated that raltitrexed inhibits SGC7901 cell growth in a dose- and time-dependent manner. The morphological changes were observed by fluorescent microscopy, and characteristic morphological changes, including nuclear shrinkage and apoptotic bodies, were observed following Hoechst 33258 staining. The effects on apoptosis, cell cycle, mitochondrial transmembrane potential and reactive oxygen species (ROS) were measured by flow cytometry. The analysis revealed that raltitrexed exerted a growth inhibitory effect by inducing time-dependent apoptosis and cell-cycle arrest at the G0/G1 phase. In addition, a compromised mitochondrial membrane potential and overproduction of ROS demonstrated the involvement of the mitochondrial signaling pathway. Raltitrexed‑induced caspase‑3‑dependent apoptosis was identified using a caspase-3 activity assay and pretreatment with the caspase-3 inhibitor, Ac‑DEVD‑CHO (sequence, Ac-Asp-Glu-Val-Asp-CHO). The activity of caspase-3 was analyzed with a spectrometer. The protein expression levels of Bax, Bcl-2, cytochrome c, cleaved caspase-3 and TS were examined by western blot and the mRNA expression level of TS was detected by quantitative polymerase chain reaction. The analysis revealed that the protein levels of Bax, cytochrome c and cleaved caspase‑3 were significantly increased by raltitrexed, while Bcl-2 expression levels were reduced. Furthermore, raltitrexed increased the expression of the TS protein and mRNA in a time‑dependent manner. These results indicate that raltitrexed induces the apoptosis of SGC7901 cells through the caspase‑3‑dependent mitochondrial signaling pathway and upregulates the expression of the TS protein and mRNA.
Insights
Raltitrexed effectively inhibits gastric cancer cell growth by inducing apoptosis via the mitochondrial pathway. This mechanism involves caspase-3 activation and upregulation of thymidylate synthase (TS) expression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Raltitrexed is a thymidylate synthase (TS) inhibitor investigated for advanced gastric cancer.
- Understanding raltitrexed's apoptosis mechanisms in gastric cancer cells is crucial for therapeutic development.
Purpose of the Study:
- To investigate the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells.
- To elucidate the role of the mitochondrial signaling pathway and caspase-3 activation in raltitrexed-induced cell death.
Main Methods:
- Cell counting kit-8 (CCK-8) assay for cytotoxicity.
- Hoechst 33258 staining and flow cytometry for apoptosis, cell cycle, mitochondrial potential, and ROS.
- Caspase-3 activity assay, Western blot, and quantitative PCR for molecular analysis.
Main Results:
- Raltitrexed inhibited SGC7901 cell growth dose- and time-dependently.
- Apoptosis was induced, evidenced by morphological changes, G0/G1 cell cycle arrest, reduced mitochondrial potential, and increased ROS.
- Raltitrexed activated caspase-3, increased Bax, cytochrome c, and cleaved caspase-3, decreased Bcl-2, and upregulated TS protein and mRNA.
Conclusions:
- Raltitrexed induces apoptosis in SGC7901 cells through a caspase-3-dependent mitochondrial pathway.
- Raltitrexed upregulates thymidylate synthase (TS) protein and mRNA expression.
- These findings support raltitrexed's potential as a chemotherapeutic agent for gastric cancer.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...


